Preview

Meditsinskiy sovet = Medical Council

Advanced search

H. pylori-associated chronic gastritis: status update on the problem

https://doi.org/10.21518/2079-701X-2022-16-15-35-45

Abstract

Chronic gastritis is a group of chronic diseases that are morphologically characterized by persistent inflammatory infiltrate and impaired cellular turnover with the development of intestinal metaplasia, atrophy, and epithelial dysplasia in the gastric mucosa. Numerous studies have shown that Helicobacter pylori (H. pylori) infection is the absolutely dominant etiological factor of CG worldwide. Given this fact, the Expert Council of the latest Maastricht VI 2022 consensus recommended that H. pylori is to be treated as a pathogen, which always results in the development of CG. The prevalence of H. pylori-associated CG is about 44.3–48.5%, however 80–90% of cases are asymptomatic. In H. pylori­infected patients with dyspepsia and no other pathology of the gastroduodenal region, which has been confirmed endoscopically, clinical manifestations can be interpreted as part of H. pylori­associated CG if a long-lasting remission of symptoms has been achieved after successful eradication therapy. While patients with persistent dyspeptic symptoms can be considered as patients with functional dyspepsia, despite successful eradication therapy. Advanced endoscopic techniques (narrow band imaging (NBI) endoscopy, high resolution endoscopy, chromoendoscopy, laser confocal endomicroscopy) are precise and reproducible methods for diagnosing precancerous changes in the mucous membrane. However, the diagnosis of CG requires that inflammatory cells have been histologically detected in the lamina propria. The CG therapy aims to reach a persistent relief of dyspeptic symptoms of the disease (if any), as well as resolution of inflammatory processes and prevention of the progression of precancerous changes in the gastric mucosa. The achievement of these goals is primarily determined by the timely diagnosis of H. pylori infection and successful eradication therapy.

About the Authors

I. V. Maev
Yevdokimov Moscow State University of Medicine and Dentistry
Russian Federation

Igor V. Maev, Acad. RAS, Dr. Sci. (Med.), Professor, Honoured Physician of RF, Honoured Worker of Science of RF, Twice RF Government Science and Engineering Prize-awarded Laureate, Head of the Department of Propaedeutics of Internal Diseases and Gastroenterology

20, Bldg. 1, Delegatskaya St., Moscow, 127473



D. N. Andreev
Yevdokimov Moscow State University of Medicine and Dentistry
Russian Federation

Dmitry N. Andreev, Cand. Sci. (Med.), Associate Professor, Associate Professor of the Department of Propaedeutics of Internal Diseases and Gastroenterology

20, Bldg. 1, Delegatskaya St., Moscow, 127473



A. A. Samsonov
Yevdokimov Moscow State University of Medicine and Dentistry
Russian Federation

Aleksey A. Samsonov, Dr. Sci. (Med.), Professor, Professor of the Department of Propaedeutics of Internal Diseases and Gastroenterology

20, Bldg. 1, Delegatskaya St., Moscow, 127473



A. K. Fomenko
Yevdokimov Moscow State University of Medicine and Dentistry
Russian Federation

Aleksey K. Fomenko, Lecturer of the Department of Pharmacology, Postgraduate Student of the Department of Propaedeutics of Internal Diseases and Gastroenterology

20, Bldg. 1, Delegatskaya St., Moscow, 127473



References

1. Ивашкин В.Т., Маев И.В., Лапина Т.Л. Федоров Е.Д., Шептулин А.А., Трухманов А.С. и др. Клинические рекомендации Российской гастроэнтерологической ассоциации и ассоциации «Эндоскопическое общество РЭНДО» по диагностике и лечению гастрита, дуоденита. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2021;31(4):70–99. https://doi.org/10.22416/1382-4376-2021-31-4-70-99. Ivashkin V.T., Maev I.V., Lapina T.L., Fedorov E.D., Sheptulin A.A., Trukhmanov A.S. et al. Clinical Recommendations of Russian Gastroenterological Association and RENDO Endoscopic Society on Diagnosis and Treatment of Gastritis and Duodenitis. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2021;31(4):70–99. (In Russ.) https://doi.org/10.22416/1382-4376-2021-31-4-70-99.

2. Feldman M., Jensen P.J., Howden C.W. Gastritis and Gastropathy. In: Feldman M., Friedman L., Brandt L. (eds.). Sleisenger and Fordtran’s Gastrointestinal and Liver Disease: Pathophysiology, Diagnosis, Management. 10th ed. Philadelphia: Saunders/Elsevier; 2020. Available at: https://www.ncbi.nlm.nih.gov/nlmcatalog/101500948.

3. Маев И.В., Андреев Д.Н., Самсонов А.А., Дичева Д.Т., ПарцваниаВиноградова Е.В. Эволюция представлений о дефиниции, классификации, диагностике и лечении гастрита, ассоциированного с инфекцией Helicobacter pylori (по материалам Киотского консенсуса, 2015). Фарматека. 2016;(6):24–33. Режим доступа: https://pharmateca.ru/ru/archive/article/32883. Maev I.V., Andreev D.N., Samsonov A.A., Dicheva D.T., Partsvania-Vinogradova E.V. The evolution of ideas about definitions, classification, diagnosis and treatment of gastritis associated with Helicobacter pylori infection (on materials of the Kyoto Consensus, 2015). Farmateka. 2016;(6):24– 33. (In Russ.) Available at: https://pharmateca.ru/ru/archive/article/32883.

4. Rugge M., Savarino E., Sbaraglia M., Bricca L., Malfertheiner P. Gastritis: The clinico-pathological spectrum. Dig Liver Dis. 2021;53(10):1237–1246. https://doi.org/10.1016/j.dld.2021.03.007.

5. Sumi N., Haruma K., Kamada T., Suehiro M., Manabe N., Akiyama T. et al. Inflammatory Cell Numbers in the Stomach of Japanese Subjects with Endoscopically Normal Mucosa without Helicobacter pylori Infection. Dig Dis. 2021;39(6):598–605. https://doi.org/10.1159/000515345.

6. Malfertheiner P., Megraud F., Rokkas T., Gisbert J.P., Liou J.M., Schulz C. et al. Management of Helicobacter pylori infection: the Maastricht VI/ Florence consensus report. Gut. 2022;71(9):1724–1762. https://doi.org/10.1136/gutjnl-2022-327745.

7. Ивашкин В.Т., Маев И.В., Каприн А.Д., Агапов М.Ю., Андреев Д.Н., Водолеев А.С. и др. Раннее выявление онкологических заболеваний органов пищеварения (методическое руководство Российской гастроэнтерологической ассоциации и Ассоциации онкологов России для врачей первичного звена здравоохранения). Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2019;29(5):53–74. https://doi.org/10.22416/1382-4376-2019-29-5-53-74. Ivashkin V.T., Mayev I.V., Kaprin A.D., Agapov M.Yu., Andreev D.N., Vodoleev A.S. et al. Early Detection of Oncological Diseases of the Digestive System (Guidelines of the Russian Gastroenterological Association and the Russian Association of Oncologists for Primary Care Physicians). Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2019;29(5):53–74. (In Russ.) https://doi.org/10.22416/1382-4376-2019-29-5-53-74.

8. Hooi J.K.Y., Lai W.Y., Ng W.K., Suen M., Underwood F., Tanyingoh D. et al. Global Prevalence of Helicobacter pylori Infection: Systematic Review and Meta-Analysis. Gastroenterology. 2017;153(2):420–429. https://doi.org/10.1053/j.gastro.2017.04.022.

9. Zamani M., Ebrahimtabar F., Zamani V., Miller M., Alizadeh-Navaei R., Shokri-Shirvani J., Derakhshan M. Systematic review with meta-analysis: the worldwide prevalence of Helicobacter pylori infection. Aliment Pharmacol Ther. 2018;47(7):868–876. https://doi.org/10.1111/apt.14561.

10. Bordin D., Morozov S., Plavnik R., Isakov V., Mayev I.V., Andreev D.N. Helicobacter pylori infection prevalence in ambulatory settings in 2017– 2019 in RUSSIA: The data of real-world national multicenter trial. Helicobacter. 2022:e12924. https://doi.org/10.1111/hel.12924.

11. Bordin D., Plavnik R., Tivanova E., Skibo I.I., Embutnieks Y.V., Maev I.V. Trends in the prevalence of Helicobacter pylori in Russia. Helicobacter. 2020;25(Suppl. 1):64–65. Available at: https://repository.rudn.ru/en/records/article/record/77575.

12. Маев И.В., Самсонов А.А., Андреев Д.Н., Гречушников В.Б., Коровина Т.И. Клиническое значение инфекции Helicobacter pylori. Клиническая медицина. 2013;91(8):4–12. Режим доступа: https://www.gastroscan.ru/literature/authors/7128. Maev I.I., Samsonov A.A., Andreev D.N., Grechushnikov V.B., Korovina T.I. Clinical significance of Helicobacter pylori infection. Clinical Medicine (Russian Journal). 2013;91(8):4–12. (In Russ.) Available at: https://www.gastroscan.ru/literature/authors/7128.

13. Маев И.В., Самсонов А.А., Андреев Д.Н., Кочетов С.А., Андреев Н.Г., Дичева Д.Т. Современные аспекты диагностики и лечения инфекции Helicobacter pylori (по материалам консенсуса Маастрихт IV, Флоренция, 2010). Медицинский совет. 2012;(8):10–19. Режим доступа: https://www.gastroscan.ru/literature/authors/7082. Maev I.V., Samsonov A.A., Andreev D.N., Kochetov S.A., Andreev N.G., Dicheva D.T. Modern aspects of diagnosis and treatment of Helicobacter pylori infection (adapted from Maastricht IV consensus, Florence, 2010) Meditsinskiy Sovet. 2012;(8):10–19. (In Russ.) Available at: https://www.gastroscan.ru/literature/authors/7082.

14. Маев И.В., Самсонов А.А., Андреев Д.Н., Кочетов С.А. Дифференцированная тактика лечения синдрома функциональной диспепсии. Медицинский совет. 2012;(9):13–20. Режим доступа: https://cyberleninka.ru/article/n/differentsirovannaya-taktika-lecheniyasindroma-funktsionalnoy-dispepsii/viewer. Maev I.V., Samsonov A.A., Andreev D.N., Kochetov S.A. Differentiated approach to the treatment of functional dyspepsia syndrome. Meditsinskiy Sovet. 2012;(9):13–20. (In Russ.) Available at: https://cyberleninka.ru/article/n/differentsirovannaya-taktika-lecheniya-sindroma-funktsionalnoydispepsii/viewer.

15. Маев И.В., Кучерявый Ю.А., Андреев Д.Н. Функциональная диспепсия: эпидемиология, классификация, этиопатогенез, диагностика и лечение. М.: СТ-Принт; 2015. 40 с. Режим доступа: https://www.gastroscan.ru/literature/authors/8552. Maev I.V., Kucheryavy Yu.A., Andreev D.N. Functional dyspepsia: epidemiology, classification, etiopathogenesis, diagnosis and treatment. Moscow: ST-Print; 2015. 40 p. (In Russ.) Available at: https://www.gastroscan.ru/literature/authors/8552.

16. Маев И.В., Самсонов А.А., Андреев Д.Н. Клиническое значение синдрома перекреста функциональной диспепсии и гастроэзофагеальной рефлюксной болезни. Клинические перспективы гастроэнтерологии, гепатологии. 2013;(5):17–22. Режим доступа: http://elib.fesmu.ru/elib/Article.aspx?id=284214. Maev I.V., Samsonov A.A., Andreev D.N. Clinical significance of the gastroesophageal reflux disease and functional dyspepsia overlap syndrome. Klinicheskie Perspektivy Gastroehnterologii, Gepatologii. 2013;(5):17–22. (In Russ.) Available at: http://elib.fesmu.ru/elib/Article.aspx?id=284214.

17. Matos J.I., de Sousa H.A., Marcos-Pinto R., Dinis-Ribeiro M. Helicobacter pylori CagA and VacA genotypes and gastric phenotype: a meta-analysis. Eur J Gastroenterol Hepatol. 2013;25(12):1431–1441. https://doi.org/10.1097/MEG.0b013e328364b53e.

18. Kpoghomou M.A., Wang J., Wang T., Jin G. Association of Helicobacter pylori babA2 gene and gastric cancer risk: a meta-analysis. BMC. Cancer. 2020;20(1):465. https://doi.org/10.1186/s12885-020-06962-7.

19. Song H., Ekheden I.G., Zheng Z., Ericsson J., Nyrén O., Ye W. Incidence of gastric cancer among patients with gastric precancerous lesions: observational cohort study in a low risk Western population. BMJ. 2015;351:h3867. https://doi.org/10.1136/bmj.h3867.

20. Dixon M.F., Genta R.M., Yardley J.H., Correa P. Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. Am J Surg Pathol. 1996;20(10):1161–1181. https://doi.org/10.1097/00000478-199610000-00001.

21. Sugano K., Tack J., Kuipers E.J., Graham D.Y., El-Omar E.M., Miura S. et al.; faculty members of Kyoto Global Consensus Conference. Kyoto global consensus report on Helicobacter pylori gastritis. Gut. 2015;64(9):1353– 1367. https://doi.org/10.1136/gutjnl-2015-309252.

22. Маев И.В., Самсонов А.А., Андреев Д.Н. Инфекция Helicobacter pylori. М.: ГЭОТАР-Медиа; 2016. 256 с. Режим доступа: http://i.uran.ru/webcab/system/files/bookspdf/infekciya-helicobacter-pylori/infekciya.pdf. Maev I.V., Samsonov A.A., Andreev D.N. Helicobacter pylori infection. Moscow: GEOTAR-Media; 2016. 256 p. (In Russ.) Available at: http://i.uran.ru/webcab/system/files/bookspdf/infekciya-helicobacter-pylori/infekciya.pdf.

23. Basso D., Plebani M., Kusters J.G. Pathogenesis of Helicobacter pylori infection. Clin Microbiol Rev. 2006;19(3):449–490. https://doi.org/10.1128/CMR.00054-05.

24. Backert S., Clyne M. Pathogenesis of Helicobacter pylori infection. Helicobacter. 2011;16(Suppl. 1):19–25. https://doi.org/10.1111/j.1523-5378.2011.00876.x.

25. Varbanova M., Frauenschläger K., Malfertheiner P. Chronic gastritis – an update. Best Pract Res Clin Gastroenterol. 2014;28(6):1031–1042. https://doi.org/10.1016/j.bpg.2014.10.005.

26. Rugge M., Sugano K., Sacchi D., Sbaraglia M., Malfertheiner P. Gastritis: An Update in 2020. Curr Treatment Options Gastroenterol. 2020;18(3):488–503. https://doi.org/10.1007/s11938-020-00298-8.

27. Alexander S.M., Retnakumar R.J., Chouhan D., Devi T.N.B., Dharmaseelan S., Devadas K. et al. Helicobacter pylori in Human Stomach: The Inconsistencies in Clinical Outcomes and the Probable Causes. Front Microbiol. 2021;12:713955. https://doi.org/10.3389/fmicb.2021.713955.

28. Ikeda F., Shikata K., Hata J., Fukuhara M., Hirakawa Y., Ohara T. et al. Combination of Helicobacter pylori Antibody and Serum Pepsinogen as a Good Predictive Tool of Gastric Cancer Incidence: 20-Year Prospective Data From the Hisayama Study. J Epidemiol. 2016;26(12):629–636. https://doi.org/10.2188/jea.JE20150258.

29. Kurilovich S., Belkovets A., Reshetnikov O., Openko T., Malyutina S., Ragino Y. et al. Stomach-specific Biomarkers (GastroPanel) Can Predict the Development of Gastric Cancer in a Caucasian Population: A Longitudinal Nested Case-Control Study in Siberia. Anticancer Res. 2016;36(1):247–253. Available at: https://pubmed.ncbi.nlm.nih.gov/26722050.

30. Bordin D.S., Voynovan I.N., Andreev D.N., Maev I.V. Current Helicobacter pylori Diagnostics. Diagnostics (Basel). 2021;11(8):1458. https://doi.org/10.3390/diagnostics11081458.

31. Best L.M., Takwoingi Y., Siddique S., Selladurai A., Gandhi A., Low B. et al. Non-invasive diagnostic tests for Helicobacter pylori infection. Cochrane Database Syst Rev. 2018;3(3):CD012080. https://doi.org/10.1002/14651858.CD012080.pub2.

32. Маев И.В., Андреев Д.Н., Кучерявый Ю.А. Хронический гастрит с позиций современной медицины. М.: Прима Принт; 2022. Maev I.V., Andreev D.N., Kucheryavyy Yu.A. Chronic gastritis interpreted in a modern medicine light. Moscow: Prima Print; 2022. (In Russ.)

33. Sugano K. Effect of Helicobacter pylori eradication on the incidence of gastric cancer: a systematic review and meta-analysis. Gastric Cancer. 2019;22(3):435–445. https://doi.org/10.1007/s10120-018-0876-0.

34. Ford A.C., Yuan Y., Moayyedi P. Helicobacter pylori eradication therapy to prevent gastric cancer: systematic review and meta-analysis. Gut. 2020;69(12):2113–2121. https://doi.org/10.1136/gutjnl-2020-320839.

35. Chen H.N., Wang Z., Li X., Zhou Z.G. Helicobacter pylori eradication cannot reduce the risk of gastric cancer in patients with intestinal metaplasia and dysplasia: evidence from a meta-analysis. Gastric Cancer. 2016;19(1):166–175. https://doi.org/10.1007/s10120-015-0462-7.

36. Rokkas T., Rokka A., Portincasa P. A systematic review and meta-analysis of the role of Helicobacter pylori eradication in preventing gastric cancer. Ann Gastroenterol. 2017;30(4):414–423. https://doi.org/10.20524/aog.2017.0144.

37. Pimentel-Nunes P., Libânio D., Marcos-Pinto R., Areia M., Leja M., Esposito G. et al. Management of epithelial precancerous conditions and lesions in the stomach (MAPS II): European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter and Microbiota Study Group (EHMSG), European Society of Pathology (ESP), and Sociedade Portuguesa de Endoscopia Digestiva (SPED) guideline update 2019. Endoscopy. 2019;51(4):365–388. https://doi.org/10.1055/a-0859-1883.

38. Андреев Д.Н., Маев И.В., Кучерявый Ю.А. Резистентность Helicobacter pylori в Российской Федерации: метаанализ исследований за последние 10 лет. Терапевтический архив. 2020;92(11):24–30. Режим доступа: https://ter-arkhiv.ru/0040-3660/article/view/56917. Andreev D.N., Maev I.V., Kucheryavyy Y.A. Helicobacter pylori resistance in the Russian Federation: a meta-analysis of studies over the past 10 years. Terapevticheskii Arkhiv. 2020;92(11):24–30. (In Russ.) Available at: https://ter-arkhiv.ru/0040-3660/article/view/56917.

39. Андреев Д.Н., Дичева Д.Т., Маев И.В. Возможности оптимизации эрадикационной терапии инфекции Helicobacter pylori в современной клинической практике. Терапевтический архив. 2017;(2):76–83. Режим доступа: https://ter-arkhiv.ru/0040-3660/issue/view/1821. Andreev D.N., Dicheva D.T., Maev I.V. Possibilities for optimization of eradication therapy for Helicobacter pylori infection in modern clinical practice. Terapevticheskii Arkhiv. 2017;(2):76–83. (In Russ.) Available at: https://ter-arkhiv.ru/0040-3660/issue/view/1821.

40. McNicholl A.G., Linares P.M., Nyssen O.P., Calvet X., Gisbert J. Metaanalysis: esomeprazole or rabeprazole vs. first-generation pump inhibitors in the treatment of Helicobacter pylori infection. Aliment Pharmacol Ther. 2012;36(5):414–425. https://doi.org/10.1111/j.1365-2036.2012.05211.x.

41. Андреев Д.Н., Кучерявый Ю.А. Факторы микро и макроорганизма, влияющие на эффективность антихеликобактерной терапии. Consilium Medicum. 2013;15(8):5–9. Режим доступа: https://consilium.orscience.ru/2075-1753/article/view/93851. Andreev D.N., Kucheryavyy Y.A. Faktory mikro i makroorganizma, vliyayushchie na effektivnost’ antikhelikobakternoy terapii. Consilium Medicum. 2013;15(8):5–9. (In Russ.) Available at: https://consilium.orscience.ru/2075-1753/article/view/93851.

42. Кучерявый Ю.А., Андреев Д.Н., Баркалова Е.В. Клинико-молекулярные аспекты резистентности Helicobacter pylori к антибактериальным препаратам. Медицинский совет. 2013;(10):11–15. https://doi.org/10.21518/2079-701X-2013-10-11-15. Kucheryaviy Y.A., Andreyev D.M., Barkalova E.V. Сlinical and molecular aspects of helicobacter pylori resistance to antimicrobial drugs. Meditsinskiy Sovet. 2013;(10):11–15. (In Russ.) https://doi.org/10.21518/2079-701X-2013-10-11-15.

43. Маев И.В., Андреев Д.Н. Молекулярно-генетические предикторы резистентности к антихеликобактерной терапии. Терапевтический архив. 2017;89(8):5–12. Режим доступа: https://ter-arkhiv.ru/0040-3660/issue/view/1827. Maev I.V., Andreev D.N. Molecular genetic predictors of resistance to antiHelicobacter pylori therapy. Terapevticheskii Arkhiv. 2017;89(8):5–12. (In Russ.) Available at: https://ter-arkhiv.ru/0040-3660/issue/view/1827.

44. Андреев Д.Н., Кучерявый Ю.А., Маев И.В. Эффективность включения масляной кислоты в схемы эрадикационной терапии инфекции Helicobacter pylori: метаанализ контролируемых исследований. Терапевтический архив. 2021;93(2):158–163. Режим доступа: https://terarkhiv.ru/0040-3660/article/view/64703. Andreev D.N., Kucheryavyy Y.A., Maev I.V. Efficacy of butyric acid inclusion in eradication regimens for Helicobacter pylori infection: a meta-analysis of controlled trials. Terapevticheskii Arkhiv. 2021;93(2):158–163. (In Russ.) Available at: https://ter-arkhiv.ru/0040-3660/article/view/64703.

45. Andreev D.N., Maev I.V., Dicheva D.T. Efficiency of the Inclusion of Rebamipide in the Eradication Therapy for Helicobacter pylori Infection: Meta-Analysis of Randomized Controlled Studies. J Clin Med. 2019;8(9):1498. https://doi.org/10.3390/jcm8091498.

46. Arakawa T., Higuchi K., Fujiwara Y., Watanabe T., Tominaga K., Sasaki E. et al. 15th anniversary of rebamipide: looking ahead to the new mechanisms and new applications. Dig Dis Sci. 2005;50(Suppl. 1):3–11. https://doi.org/10.1007/s10620-005-2800-9.

47. Андреев Д.Н., Маев И.В. Ребамипид: доказательная база применения в гастроэнтерологии. Терапевтический архив. 2020;92(12):97–104. https://doi.org/10.26442/00403660.2020.12.200455. Andreev D.N., Maev I.V. Rebamipide: evidence base for use in gastroenterology. Terapevticheskii Arkhiv. 2020;92(12):97–104. https://doi.org/10.26442/00403660.2020.12.200455.

48. Li M., Yin T., Lin B. Rebamipide for chronic gastritis: a meta-analysis. Chinese J Gastroenterol Hepatol. 2015;24:667–673.

49. Haruma K., Ito M., Kido S., Manabe N., Kitadai Y., Sumii M. et al. Longterm rebamipide therapy improves Helicobacter pylori-associated chronic gastritis. Dig Dis Sci. 2002;47(4):862–867. https://doi.org/10.1023/a:1014716822702.

50. Kamada T., Sato M., Tokutomi T., Watanabe T., Murao T. , Matsumoto H. et al. Rebamipide improves chronic inflammation in the lesser curvature of the corpus after Helicobacter pylori eradication: a multicenter study. Biomed Res Int. 2015;2015:865146. https://doi.org/10.1155/2015/865146.


Review

For citations:


Maev IV, Andreev DN, Samsonov AA, Fomenko AK. H. pylori-associated chronic gastritis: status update on the problem. Meditsinskiy sovet = Medical Council. 2022;(15):35-45. (In Russ.) https://doi.org/10.21518/2079-701X-2022-16-15-35-45

Views: 659


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 2079-701X (Print)
ISSN 2658-5790 (Online)